Multiple Sclerosis (MS)
is a chronic, progressive neurologic disease characterized by
scattered demyelination of nerve fibers in the brain and spinal
cord. Fatigue, vertigo, spasticity and muscle spasms,
psychological problems, urinary dysfunction, sexual problems
,tremors and incoordination, pain and cognitive problems are some
of the associated effect of MS. Within 40 years of its first
depiction, the clinical and pathological details of multiple
sclerosis had been adequately characterised. Over the past 120
years, ideas have consolidated on the cause and mechanisms of
inflammatory demyelination and axonopathy. In the past 10 years,
therapies have emerged that modestly affect the course of the
illness. Current research is increasingly seen as coherent and
focused on the hot topics that need to be solved to limit, repair,
and prevent the damage caused by multiple sclerosis.
The use of the Cytotron� in the treatment of
Multiple Sclerosis has shown extremely promising results. Based on
these preliminary results from patients treated with the Cytotron�,
S-CARD, Bangalore has registered a trial for Multiple Sclerosis
with the NIH clinicaltrials.gov (NCT01220830).
The purpose of the study is to evaluate the efficacy of RFQMR
therapy in remyelination in cases of Multiple sclerosis. The
evaluation will be done based on MRI findings, by clinical/
neurological examination and by assessment of quality of life
before and after completion of therapy.
Shreis plans to repeat a similar trial here in the US.
Shreis has already commenced work in Canada for a study of MS patients and to follow it with a clinical trial as per Health Canada regulations.
SHREIS HAS THE MARKETING RIGHTS ALSO FOR MULTIPLE SCLEROSIS FOR NORTH AND SOUTH AMERICAS AND THE CARIBBEAN INCLUDING MEXICO
Clinical Trial registered with NIH ClinicalTrials.gov Identifier: NCT01220830
